Rheumatology Advance Access published online on March 3, 2008
Rheumatology, doi:10.1093/rheumatology/ken002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
1Department of Rheumatology, Lund University Hospital, SE-221 85 Lund and 2Department of Rheumatology, Spenshult, SE-313 92 Oskarström, Sweden.
Correspondence to:
L. E. Kristensen, Department of Rheumatology, Lund University Hospital, SE-221 85 Lund, Sweden. E-mail: larserik_kristensen{at}yahoo.com
 |
Abstract |
|---|
Objective. To identify factors predicting response to first TNF blocking treatment course in patients with established RA with a special focus on gender differences.
Methods. Patients with active RA initiating their first treatment course of TNF-blocking therapy were enrolled. The study period was March 1999 through September 2006. The prospective protocol included information on demographics, clinical characteristics of patients and response measures. Fulfilment of ACR 50–70% improvement and European League Against Rheumatism (EULAR) good response or remission [28-joint disease activity score (DAS28) <2.6] at 3 months were chosen as primary outcome measures. Potential predictors of responses were identified using multivariate binary logistic regression models.
Results. In total, 1565 patients were included in the study. Gender did not influence treatment response. Consistently, concomitant methotrexate (MTX) was significantly associated with EULAR remission, EULAR good response, ACR50 response and ACR70 response with odds ratios (ORs) 1.97, 2.13, 2.10 and 1.75, respectively. Concurrent treatment with other DMARDs was also significantly associated with EULAR remission, EULAR good response and ACR50 response (OR: 1.96, 2.24 and 1.94, respectively). Likewise, low HAQ at baseline consistently predicted good clinical outcome. Disease activity at baseline was directly associated with favourable response when measured by ACR50 and ACR70 (OR: 1.59 and 1.60, respectively), whereas DAS28 score at baseline was inversely associated with EULAR remission (OR: 0.78).
Conclusion. In this observational study of patients with established RA, gender did not predict response to anti-TNF therapy, whereas treatment with concomitant DMARDs, especially MTX and low disability were associated with good response. Choice of outcome measures may influence the predictive value of baseline features.
KEY WORDS: Response, Anti-TNF-
therapy, Biologics register, Predictors, Rheumatoid arthritis
Submitted 10 August 2007;
revised version accepted 2 January 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. Hyrich, C. Deighton, K. D. Watson, BSRBR Control Centre Consortium, D. P. M. Symmons, M. Lunt, and on behalf of the British Society for Rheumatology Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity Rheumatology, October 1, 2009; 48(10): 1323 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Quartuccio, M. Fabris, S. Salvin, F. Atzeni, M. Saracco, M. Benucci, M. Cimmino, P. Morassi, P. Masolini, R. Pellerito, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis Rheumatology, September 29, 2009; (2009) kep314v1. [Abstract] [Full Text] [PDF]
|
|